Evidence map›Paper›PMID 26176265›Full record

Trial reportStem cells and development2015

Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke Patients.

Akihiko Taguchi, Chiaki Sakai, Toshihiro Soma, Yukiko Kasahara, David M Stern, Katsufumi Kajimoto, Masafumi Ihara, Takashi Daimon, Kenichi Yamahara, Kaori Doi and 6 more

Open access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cells and development, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 6 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 6 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. A review and meta-analysis of stem cell therapies in stroke patients: effectiveness and safety evaluation.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Pooled it
  2. Pooled it
  3. Stem cell transplantation for ischemic stroke.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Akihiko Taguchi1 Department of Regenerative Medicine Research, Institute of Biomedical Research and Innovation , Kobe, Japan .
Chiaki Sakai3 Department of Endovascular Therapy, Institute of Biomedical Research and Innovation , Kobe, Japan .
Toshihiro Soma5 Department of Hematology, Hyogo College of Medicine , Nishinomiya, Japan .
Yukiko Kasahara1 Department of Regenerative Medicine Research, Institute of Biomedical Research and Innovation , Kobe, Japan .
David M Stern6 Executive Dean's Office, University of Tennessee , Memphis, Tennessee.
Katsufumi Kajimoto2 Department of Neurology, National Cerebral and Cardiovascular Center , Suita, Japan .
Masafumi Ihara1 Department of Regenerative Medicine Research, Institute of Biomedical Research and Innovation , Kobe, Japan .
Takashi Daimon7 Department of Biostatistics, Hyogo College of Medicine , Nishinomiya, Japan .
Kenichi Yamahara8 Department of Regenerative Medicine, National Cerebral and Cardiovascular Center , Suita, Japan .
Kaori Doi9 Department of Nursing, National Cerebral and Cardiovascular Center , Suita, Japan .
Nobuo Kohara10 Department of Neurology, Kobe City Medical Center General Hospital , Kobe, Japan .
Hiroyuki Nishimura11 Department of Neurology, Nishinomiya Kyoritsu Neurosurgical Hospital , Nishinomiya, Japan .
Tomohiro Matsuyama12 Institute for Advanced Medical Sciences, Hyogo College of Medicine , Nishinomiya, Japan .
Hiroaki Naritomi2 Department of Neurology, National Cerebral and Cardiovascular Center , Suita, Japan .
Nobuyuki Sakai3 Department of Endovascular Therapy, Institute of Biomedical Research and Innovation , Kobe, Japan .
Kazuyuki Nagatsuka2 Department of Neurology, National Cerebral and Cardiovascular Center , Suita, Japan .
National Cerebral and Cardiovascular Center · JPHyogo Medical University · JPInstitute for Biomedical Research and Innovation · ITKobe City Medical Center General Hospital · JPNishinomiya Kyoritsu Neurosurgical Hospital · JPUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The goal of this clinical trial was to assess the feasibility and safety of transplanting autologous bone marrow mononuclear cells into patients suffering severe embolic stroke. Major inclusion criteria included patients with cerebral embolism, age 20-75 years, National Institute of Health Stroke Scale (NIHSS) score displaying improvement of ≤ 5 points during the first 7 days after stroke, and NIHSS score of ≥ 10 on day 7 after stroke. Bone marrow aspiration (25 or 50 mL; N = 6 patients in each case) was performed 7-10 days poststroke, and bone marrow mononuclear cells were administrated intravenously. Mean total transplanted cell numbers were 2.5 × 10(8) and 3.4 × 10(8) cells in the lower and higher dose groups, respectively. No apparent adverse effects of administering bone marrow cells were observed. Compared with the lower dose, patients receiving the higher dose of bone marrow cells displayed a trend toward improved neurologic outcomes. Compared with 1 month after treatment, patients receiving cell therapy displayed a trend toward improved cerebral blood flow and metabolic rate of oxygen consumption 6 months after treatment. In comparison with historical controls, patients receiving cell therapy had significantly better neurologic outcomes. Our results indicated that intravenous transplantation of autologous bone marrow mononuclear cells is safe and feasible. Positive results and trends favoring neurologic recovery and improvement in cerebral blood flow and metabolism by cell therapy underscore the relevance of larger scale randomized controlled trials using this approach.

Indexed as

Administration, IntravenousAgedAntigens, CD34Bone Marrow CellsBone Marrow TransplantationCerebrovascular CirculationCytokinesFemaleHumansIntercellular Signaling Peptides and ProteinsLeukocyte CountLeukocytes, MononuclearMaleMiddle AgedOxygenRecurrenceAntigens, CD34CytokinesIntercellular Signaling Peptides and ProteinsOxygen

Identifiers

PMID26176265
PMCPMC4582686
OpenAlexW2237017481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.